Drugs / Gemcitabine (GEM)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07383922 Background | Feb 2026 → Jun 2030 expected | malignant pancreatic neoplasm | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gemcitabine (GEM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383922 ↗ |
| Route | Intravenous | “Gemcitabine will be administered as an Intravenous drip.” NCT07383922 ↗ |